Celldex Therapeutics Inc.

7 trials 2 recruiting Commercial sponsor

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

2 Recruiting

5 Completed trials

17 Countries active

2 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 4 Phase II: 3

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Chronic spontaneous urticaria 3 Urticaria 1

Top IMPs

BARZOLVOLIMAB 7 EPINEPHRINE 5

All trials

7 total

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting

2025-522878-36-00 Phase III 16 countries BARZOLVOLIMAB; EPINEPHRINE
Phase 3 Study of Barzolvolimab in Participants with Cold Induced Urticaria and Symptomatic Dermographism Recruiting

2025-522583-32-00 Phase III 4 countries BARZOLVOLIMAB; EPINEPHRINE
A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513210-36-00 Phase III 10 countries BARZOLVOLIMAB; EPINEPHRINE
A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513208-32-00 Phase III 11 countries BARZOLVOLIMAB; EPINEPHRINE
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Prurigo No… Ended

2023-510279-80-00 Phase II 4 countries BARZOLVOLIMAB
A Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The… Ended

2024-512767-30-00 Phase II 4 countries BARZOLVOLIMAB; EPINEPHRINE
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose ranging Study to Assess the Efficacy and Safety of CDX 0159 in Patients with Ch… Ended

2024-516988-87-00 Phase II 7 countries BARZOLVOLIMAB

Showing 1–7 of 7 trials

← All sponsors A–Z